US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

HeartFlow Inc. (HTFL): Healthcare AI IPO Opens Strong, Trades Steady on Heavy Demand

Pre-IPO Heartflow (HTFL US - Thoughts on the Business and Valuation Outlook

HeartFlow Inc. (HTFL): Peeking at the IPO Prospectus of Coronary Artery Disease Patient Care Company

HeartFlow Inc. (HTFL): Coronary Artery Disease Company Sets Terms Seeking up to $1.3b Valuation

Pre-IPO Sichuan Neautus Traditional Chinese Medicine - The Outlook Is Not Optimistic

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>HeartFlow is offering 12.5 million shares at a $15-$17 range which equates to a valuation of around $1.32 billion. </li>
<li>According to guidance the deal is being classified as oversubscribed with early long-only and healthcare dedicated conversions. </li>
<li>Combine durable revenues, strong underwriting and backers with a tailwind from a healthcare segment with a touch of AI, it is our opinion that this IPO will be well-received.</li>
</ul>


HeartFlow is offering 12.5 million shares at a $15-$17 range which equates to a valuation of around $1.32 billion. 
According to guidance the deal is being classified as oversubscribed with early long-only and healthcare dedicated conversions. 
Combine durable revenues, strong underwriting and backers with a tailwind from a healthcare segment with a touch of AI, it is our opinion that this IPO will be well-received.


HeartFlow Inc. (HTFL): Revenue Growth, Strong Margin Profile Highlights IPO Bull Case